Shareholders With Considerable Losses Have Prospect to Lead the Athira Pharma, Inc. Class Action Lawsuit

San Diego, California–(Newsfile Corp. – July 15, 2021) – The Athira Pharma course action lawsuit rates Athira Pharma, Inc. (NASDAQ: ATHA) and its CEO with violations of the Securities Trade Act of 1934 and seeks to depict purchasers of Athira Pharma securities among September 18, 2020 and June 17, 2021, inclusive (the “Class Period”). The Athira Pharma class motion lawsuit was commented in the Western District of Washington and is captioned Wang v. Athira Pharma, Inc., No. 21-cv-00861. Two comparable lawsuits – Jawandha v. Athira Pharma, Inc., No. 21-cv-00862, and Slyne v. Athira Pharma, Inc., No. 21-cv-00864 – are also pending in the Western District of Washington.

If you endured considerable losses and would like to provide as lead plaintiff of the Athira Pharma course action lawsuit, you should present your details by clicking below. You can also call attorney J.C. Sanchez of Robbins Geller by contacting 800/449-4900 or by way of e-mail at [email protected]. Lead plaintiff motions for the Athira Pharma course action lawsuit have to be filed with the court no later than August 24, 2021.

Circumstance ALLEGATIONS: The Athira Pharma class motion lawsuit alleges that, during the Course Interval, defendants produced untrue and misleading statements and failed to disclose that: (i) the investigate conducted by Athira Pharma’s President and Chief Executive Officer, defendant Leen Kawas, which shaped the foundation for Athira Pharma’s solution candidates and intellectual property, was tainted by Kawas’s scientific misconduct, together with the manipulation of important facts and (ii) as a result, defendants’ constructive statements about Athira Pharma’s business enterprise, operations, and prospects were materially deceptive and omitted material info necessary to make the statements designed not misleading.

On June 17, 2021, Athira Pharma issued a press launch saying that Athira Pharma’s Board of Administrators had put Kawas on short term leave pending a review of steps stemming from doctoral research Kawas carried out even though at Washington Condition University. An posting published in STAT Information afterwards that day exposed that the investigation of Kawas associated to allegations that she altered illustrations or photos in four separate papers relating to her investigation on hepatocyte growth factor (HGF), a protein with the potential to handle Alzheimer’s illness and other neurological diseases. The write-up pointed out that although Athira Pharma “has since moved on to a unique molecule than the 1 Kawas was functioning on, it however aims to target HGF. And so Kawas’s doctoral function laid the organic groundwork that Athira proceeds to use in their tactic to treating Alzheimer’s.” On this news, Athira Pharma’s stock price fell by almost 39%, harmful buyers.

THE Direct PLAINTIFF System: The Personal Securities Litigation Reform Act of 1995 permits any investor who obtained Athira Pharma securities for the duration of the Course Time period to seek appointment as guide plaintiff in the Athira Pharma class action lawsuit. A direct plaintiff is typically the movant with the greatest economical fascination in the aid sought by the putative course who is also typical and sufficient of the putative course. A lead plaintiff acts on behalf of all other course members in directing the Athira Pharma course motion lawsuit. The guide plaintiff can find a regulation business of its decision to litigate the Athira Pharma course motion lawsuit. An investor’s skill to share in any possible future recovery of the Athira Pharma course action lawsuit is not dependent upon serving as lead plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 legal professionals in 9 places of work nationwide, Robbins Geller Rudman & Dowd LLP is the biggest U.S. regulation agency symbolizing buyers in securities class steps. Robbins Geller attorneys have attained many of the greatest shareholder recoveries in background, which include the major securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Expert services Top 50 Report rated Robbins Geller initially for recovering $1.6 billion for buyers past yr, much more than double the volume recovered by any other securities plaintiffs’ business. Please pay a visit to https://www.rgrdlaw.com/firm.html for additional information and facts.

Lawyer advertising and marketing.

Past results do not warranty future results.

Companies may well be carried out by attorneys in any of our places of work.

Get in touch with:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]